OncoMatch/Clinical Trials/NCT06446713
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
Is NCT06446713 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for head and neck cancer.
In this study the safety \& feasibility of image-guided mid-treatment hyper-fractioned dose-escalation with proton therapy will be assessed for the treatment of locally advanced HPV-negative squamous cell oropharyngeal cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A wild-type
Negative for p16
Disease stage
Required: Stage III, IV
Prior therapy
Cannot have received: definitive resection
Exception: incisional or excisional biopsies
underwent definitive resection of their primary tumor or nodal disease, except for incisional or excisional biopsies
Cannot have received: radiation therapy
received radiation therapy in the head and neck area in the past
Lab requirements
Kidney function
estimated gfr < 60 ml/min/1.73 m2 or any contraindications to gadolinium-based contrast agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify